Vinayak T Bhalani

US Patent:

7070802, Jul 4, 2006

Filed:

Mar 5, 2001

Appl. No.:

09/797912

Inventors:

Vinayak T. Bhalani - Livingston NJ, US
Satishchandra P. Patel - Livingston NJ, US

Assignee:

Pliva, Inc. - East Hanover NJ

International Classification:

A61K 9/66
A61K 9/48
A61K 9/64

US Classification:

424455, 424451, 424452, 424456

Abstract:

Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C-Cfatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

US Patent:

7799340, Sep 21, 2010

Filed:

Mar 15, 2007

Appl. No.:

11/686555

Inventors:

Vinayak T. Bhalani - Livingston NJ, US
Satishchandra P. Patel - Livingston NJ, US

Assignee:

Watson Laboratories, Inc. - Corona CA

International Classification:

A61K 9/66
A61K 9/48
A61K 9/64

US Classification:

424455, 424451, 424452, 424456, 514 11, 514937, 514938

Abstract:

Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C-Cfatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

US Patent:

7988995, Aug 2, 2011

Filed:

Jul 30, 2002

Appl. No.:

10/207146

Inventors:

Vinayak T. Bhalani - Livingston NJ, US
Satishchandra P. Patel - Livingston NJ, US

Assignee:

Watson Laboratories, Inc. - Corona CA

International Classification:

A61K 9/48
A61K 9/64
A61K 9/66

US Classification:

424455, 424451, 424452, 424456

Abstract:

Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C-Cfatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

US Patent:

20060188561, Aug 24, 2006

Filed:

Apr 7, 2006

Appl. No.:

11/400585

Inventors:

Vinayak Bhalani - Livingston NJ, US
Satishchandra Patel - Livingston NJ, US

Assignee:

Pliva, Inc. (formerly known as Sidmak Laboratories, Inc.) - East Hanover NJ

International Classification:

A61K 38/13
A61K 9/127
A61K 36/47

US Classification:

424450000, 514011000, 977907000, 424731000

Abstract:

Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C-Cfatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

US Patent:

20120135940, May 31, 2012

Filed:

Jan 12, 2012

Appl. No.:

13/349138

Inventors:

Vinayak T. BHALANI - Livingston NJ, US
Satishchandra P. PATEL - Livingston NJ, US

Assignee:

WATSON LABORATORIES, INC. - Corona CA

International Classification:

A61K 38/13
B82Y 5/00

US Classification:

514 205, 977788, 977915

Abstract:

Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C-Cfatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

US Patent:

54076862, Apr 18, 1995

Filed:

Jan 29, 1992

Appl. No.:

7/827604

Inventors:

Satischandra P. Patel - Livingston NJ
Vinayak T. Bhalani - Morris Plains NJ

Assignee:

Sidmak Laboratories, Inc. - East Hanover NJ

International Classification:

A61K 922

US Classification:

424468

Abstract:

A sustained release tablet adapted to provide an initial immediate release of an active agent, a period of no release of the active agent, followed by a substantially constant, rate of release of the active agent. The tablet includes (a) a compressed tablet core containing an active agent, an insoluble binder and an insoluble; (b) a barrier coating formed over the tablet core, the barrier coating including a mixture of soluble and insoluble polymers and a plasticizer; (c) an active coating deposited over the barrier coating, the active coating including an active agent, a soluble polymer and a plasticizer; and (d) a film coating formed over the active coating, the film coating containing a soluble polymer and plasticizer.

US Patent:

58584013, Jan 12, 1999

Filed:

Jan 22, 1997

Appl. No.:

8/786314

Inventors:

Vinayak T. Bhalani - Livingston NJ
Satishchandra P. Patel - Livingston NJ

Assignee:

Sidmak Laboratories, Inc. - East Hanover NJ

International Classification:

A61K 948

US Classification:

424450

Abstract:

The invention comprises a stable solution of cyclosporine forming a polar lipid self-emulsifying drug delivery system ("PLSEDDS"). The composition typically consists of cyclosporine dissolved in a polar lipid, such as a medium chain monoglyceride of C. sub. 6 -C. sub. 12 fatty acids having a monoglyceride content of at least 50% and a surfactant. The composition provided here instantly forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

US Patent:

50431684, Aug 27, 1991

Filed:

Apr 26, 1990

Appl. No.:

7/514558

Inventors:

Satishchandra P. Patel - Livingston NJ
Vinayak T. Bhalani - Morris Plains NJ

Assignee:

Sidmak Laboratories, Inc. - East Hanover NJ

International Classification:

A61K 3160
A61K 4700

US Classification:

424682

Abstract:

A stable, solid choline magnesium salicylte inclusion complex composition which comprises choline salicylate, magnesium salicylate and magnesium aluminum silicate, and granulation method for preparing the solid inclusion complex composition utilizing liquid salicylate is provided. The invention is also directed to methods of administering the compoitions of the invention to treat osteoarthritis, rheumatoid arthritis, and acute painful shoulder.